Back to Search Start Over

Tissue Stromal Vascular Fraction Improves Early Scar Healing

Authors :
Joris A van Dongen
Joeri van Boxtel
Mustafa Uguten
Linda A Brouwer
Karin M Vermeulen
Wynand B Melenhorst
Frank B Niessen
Martin C Harmsen
Hieronymus P Stevens
Berend van der Lei
Plastic, Reconstructive and Hand Surgery
AII - Inflammatory diseases
AMS - Tissue Function & Regeneration
Value, Affordability and Sustainability (VALUE)
Restoring Organ Function by Means of Regenerative Medicine (REGENERATE)
Source :
Aesthetic Surgery Journal, 42(7), NP477-NP488. SAGE Publications Inc., Aesthetic Surgery Journal, 42(7):431, NP477-NP488. Oxford University Press, van Dongen, J A, van Boxtel, J, Uguten, M, Brouwer, L A, Vermeulen, K M, Melenhorst, W B, Niessen, F B, Harmsen, M C, Stevens, H P & van der Lei, B 2022, ' Tissue Stromal Vascular Fraction Improves Early Scar Healing : A Prospective Randomized Multicenter Clinical Trial ', Aesthetic Surgery Journal, vol. 42, no. 7, pp. NP477-NP488 . https://doi.org/10.1093/asj/sjab431
Publication Year :
2022

Abstract

Background Wound healing and scar formation depends on a plethora of factors. Given the impact of abnormal scar formation, interventions aimed to improve scar formation would be most advantageous. The tissue stromal vascular fraction (tSVF) of adipose tissue is composed of a heterogenous mixture of cells embedded in extracellular matrix. It contains growth factors and cytokines involved in wound-healing processes, eg, parenchymal proliferation, inflammation, angiogenesis, and matrix remodeling. Objectives The aim of this study was to investigate the hypothesis that tSVF reduces postsurgical scar formation. Methods This prospective, double-blind, placebo-controlled, randomized trial was conducted between 2016 and 2020. Forty mammoplasty patients were enrolled and followed for 1 year. At the end of the mammoplasty procedure, all patients received tSVF in the lateral 5 cm of the horizontal scar of 1 breast and a placebo injection in the contralateral breast to serve as an intrapatient control. Primary outcome was scar quality measure by the Patient and Observer Scar Assessment Scale (POSAS). Secondary outcomes were obtained from photographic evaluation and histologic analysis of scar tissue samples. Results Thirty-four of 40 patients completed follow-up. At 6 months postoperation, injection of tSVF had significantly improved postoperative scar appearance as assessed by the POSAS questionnaire. No difference was observed at 12 months postoperation. No improvement was seen based on the evaluation of photographs and histologic analysis of postoperative scars between both groups. Conclusions Injection of tSVF resulted in improved wound healing and reduced scar formation at 6 months postoperation, without any noticeable advantageous effects seen at 12 months. Level of Evidence: 2

Details

Language :
English
ISSN :
1090820X
Volume :
42
Issue :
7
Database :
OpenAIRE
Journal :
Aesthetic Surgery Journal
Accession number :
edsair.doi.dedup.....9e5e15e7c08b7f9fe60b696442afc1a7
Full Text :
https://doi.org/10.1093/asj/sjab431